Prestige Consumer Healthcare Inc (PBH) Stock Analysis
Verdict: WATCH (do not buy)
High FCF yield (11.1%) and low beta (0.32) cushion top-line decline (-1.36%), but high debt ($1.05B) caps near-term re-rating potential.
Investment score: 57/100
Analysis as of
Is Prestige Consumer Healthcare Inc stock worth reviewing? AI model thesis
The AI model sees Prestige Consumer Healthcare as a high-cash-generation, low-beta defensive stock trading at a discount, balanced by negative top-line momentum and leverage.
7-factor investment score
- Valuation: 75/100 (weight 20%)
- Financial Health: 55/100 (weight 15%)
- Technical Momentum: 35/100 (weight 15%)
- Earnings Quality: 60/100 (weight 15%)
- Insider Sentiment: 35/100 (weight 10%)
- Analyst Consensus: 65/100 (weight 10%)
- Risk-Adjusted Return: 65/100 (weight 15%)
Prestige Consumer Healthcare Inc opportunities and risks
What speaks for PBH
- Robust free cash flow yield provides structural downside protection and debt paydown capacity
What speaks against PBH
- Top-line revenue contraction driven by over-the-counter post-pandemic normalization
Frequently asked questions about Prestige Consumer Healthcare Inc (PBH)
Is PBH stock a good investment?
The cached TradeMates AI model rates Prestige Consumer Healthcare Inc as WATCH (do not buy) with an investment score of 57/100. The AI model sees Prestige Consumer Healthcare as a high-cash-generation, low-beta defensive stock trading at a discount, balanced by negative top-line momentum and leverage. This is algorithmic model output, not personal investment advice.
Is PBH stock a buy?
The TradeMates model verdict for PBH is WATCH (do not buy) with an investment score of 57/100. Treat this as a model signal to review, not a personal buy recommendation.